Analysts/Institutional Investor Meet/Con. Call Updates

Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 Date: 29 July 2026 Corporate Relationship Department, National Stock Exchange of India Limited BSE Limited Exchange Plaza, 5th Floor, Phiroze Jeejeebhoy Towers, Plot No.C/1, G Block Dalal Street, Fort, Bandra Kurla Complex, Bandra (E) Mumbai-400 001 Mumbai-400 051 Dear Madam/Sir, Sub: Analysts/Investors call Ref: Stock Code: NSE: SHILPAMED/BSE-530549 Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q1- FY27 Earnings Conference Call, which is to be held on Wednesday, August 05, 2026, at 16.00 hrs. A copy of this intimation is also being made available at: https://www.vbshilpa.com/investor-presentation.php We request you to take the above information on record. Thanking you. Yours faithfully, For Shilpa Medicare Limited Ritu Tiwary Company Secretary Shilpa Medicare Limited 1QFY27 Earnings Conference Call Shilpa Medicare Limited (BSE:530549; NSE: SHILPAMED)will announceits results for the first quarter ended June 30, 2026, on Wednesday, August 05, 2026 Themanagement of the Company will host its earningscall on Wednesday, August 05, 2026at 16:00 hrs Details of Earnings Conference Call Day/Date Wednesday, August 05, 2026 Time 16:00 hrs Universal Access +91 22 6280 1130 +91 22 7115 8031 The number listed above is universally accessible from all networks and all countries International Toll-Free Numbers USA 18667462133 UK 08081011573 Singapore 8001012045 Hong Kong 800964448 DiamondPass Link Click here to join with DiamondPass (No Wait Time) Participants are requested to dial-in 10 minutes before the scheduled time About Shilpa Medicare Limited (SML) Shilpa Medicare Limited (SML) is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio. The company alsoprovidesend-to-endCDMOservicestoglobalpharmaceuticalcompaniesacrossallitsbusinesssegments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities. For more information, visit www.vbshilpa.com Forfurtherdetails,pleasegetintouchwith ShilpaMedicareLtd MonishShah E: monish.shah@vbshilpa.com